

## Highlights in therapy-related myeloid neoplasms

February 9<sup>th</sup>-10<sup>th</sup>, 2023

AIL Headquarters, Via Casilina 5, Rome, Italy

[www.nanaonlus.org/tmn2023/](http://www.nanaonlus.org/tmn2023/)

### **SCIENTIFIC PROGRAMME**

#### **Day 1**

<b>12:00 - 13:50</b>	<b>Registration and light "Get Together" lunch</b>
	<p>In the main hall, the following scientific posters by early career scientists will be on display for the entire meeting:</p> <p><i>Maria Badikyan</i>, Yerevan Armenia, Secondary acute myeloid leukemia following chemotherapy for a rare type DLBCL.</p> <p><i>Gaetano Cimino</i>, Perugia, Italy, <i>NUP98::TOP1</i> fusion gene in therapy-related acute myeloid leukemia: 2 case reports and their successful therapeutic strategy.</p> <p><i>Liana Hambarzumyan</i>, Yerevan Armenia, Therapy related acute myeloid leukemia in a patient with systemic lupus erythematosus.</p> <p><i>Elif Berna Köksoy</i>, Therapy-related myelodysplastic syndrome (t-MDS) and therapy related myeloproliferative neoplasms (t-MPN): a single-centre experience.</p> <p><i>Nareh Martirosyan</i>, Yerevan, Armenia, Therapy related myelodysplastic syndrome: A case report.</p> <p><i>Merve Yüksel</i>, Ankara, Turkey, Therapy related myeloid neoplasms: Case report.</p>
13:50 – 14:00	<p>Welcome address</p> <p>M.T. Voso (University of Rome Tor Vergata, Italy) D. Capone (NA<sup>NA</sup> ETS, Rome, Italy)</p>
	<p><b>Clinical picture of t-MN</b></p> <p>Chairs: G. Leone (Catholic University of the Sacred Heart, Rome, Italy) A. Venditti (University of Rome Tor Vergata, Italy)</p>
14:00 – 14:25	<p>Overview and epidemiology of therapy-related myeloid neoplasms</p> <p>L.S. Granfeldt-Ostgard, Odense University Hospital, Denmark</p>
14:30 – 14:55	<p>2022 update of AML classification</p> <p>K. Döhner, University of Ulm, Germany</p>
15:00 – 15:25	<p>Clinical presentation of t-MN</p> <p>F. Buccisano, University of Rome Tor Vergata, Italy</p>
15:30 – 15:55	<p>Genetic susceptibility to AML</p> <p>J. Allan, Newcastle University, UK</p>
<b>16:00 - 16:30</b>	<b>Coffee break</b>
	<p><b>Biology of t-MN</b></p> <p>Chairs: K. Döhner (University of Ulm, Germany) C. Niemeyer (Albert-Ludwigs Universität Freiburg, Germany)</p>
16:30 – 16:55	<p>Cytogenetic and molecular profile of t-MN</p> <p>S. Galimberti, University of Pisa, Italy</p>
17:00 – 17:25	<p>Clonal evolution in therapy-related myeloid neoplasms</p> <p>E. Fabiani, University of Rome Tor Vergata, Italy</p>
17:30 – 17:55	<p>Microenvironment involvement in t-MN</p> <p>G. Falconi, University of Rome Tor Vergata, Italy</p>

## Day 2

	<b>New perspectives for t-MN research and care</b> Chairs: G. Ciliberto (IRCCS Regina Elena National Cancer Institute, Rome, Italy) L. Pagano (Catholic University of the Sacred Heart, Rome, Italy)
09:00 – 09:25	t-MN: the oncologist's point of view D. Lorusso, Policlinico Gemelli, Rome, Italy
09:30 – 09:55	Biology of t-APL T. Ottone, University of Rome, Tor Vergata, Italy
10:00 – 10:25	Clinical presentation and outcome of t-APL R. Dillon, King's College, London, UK
10:30 – 10:55	t-MN following childhood malignancies F. Locatelli, Catholic University of the Sacred Heart, Rome, Italy
<b>11:00 - 11:30</b>	<b>Coffee break</b>
<b>11:30 - 12:30</b>	<b>Selected abstract presentations by early career scientists</b> Chairs: M.T. Voso (University of Rome Tor Vergata, Italy) K. Döhner (University of Ulm, Germany)
11:30 – 11:45	2022 classifications of secondary acute myeloid leukemias E. Attardi, University of Rome, Tor Vergata, Italy
11:45 – 12:00	Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes arising from Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria C. Gurnari, University of Rome, Tor Vergata, Italy
12:00 – 12:15	A case report of acute myeloid leukemia following exposure to cytotoxic therapy for breast cancer A. Movsysian, Hematology Center after Prof. R.H. Yeolyan, Yerevan, Armenia
12:15 – 12:30	Therapy-related AML after breast cancer: 5 case series M. Aydogan, Ankara University, Faculty of Medicine, Turkey
<b>12:30 – 13:30</b>	<b>Round table “The patient social point of view”</b> Moderators: G. Ciliberto (IRCCS Regina Elena National Cancer Institute of Rome, Italy) G. Martini (NA <sup>n</sup> A ETS, Rome, Italy) Participants: F. Bombaci (AIL Patients, Torino, Italy) B. Ryll (Melanoma Patient Network Europe) A. Sidoli (AXXAM, Milan, Italy)
<b>13:30 - 14:00</b>	<b>Light lunch</b>
	<b>Leukaemogenic drugs and treatment of t-MN</b> Chairs: J. Mayer (University Hospital, Brno, Czech Republic) M.K.Yuksel (Ankara University, Turkey)
14:00 – 14:25	Leukaemogenic effects of topoisomerase inhibitors, alkylating agents and new drugs R. Danesi, University of Pisa, Italy
14:25 – 14:50	Available therapeutic options and new treatments for t-MN L. Fianchi, Policlinico Gemelli, Rome, Italy
<b>14:55 – 15:15</b>	<b>Closing Remarks</b>